NextCure Inc (NXTC)

Official site

HEALTHCARE • BIOTECHNOLOGY • NASDAQ

$6.88

+0.30 (+4.56%)

Market Cap: $30.12M

Last updated: Oct 16, 2026 at 1:55 PM ET

Earnings

Performance (10Y)

Beat Rate

53%(16/30)

Avg Surprise

-20.78%

Streak

4 Q

Upcoming Estimates

Period ending Sep 30, 2026

EPS Consensus$-0.90

Range$-0.90 - $-0.90

1 analysts

EPS RevisionsNo revisions (7d)No revisions (30d)

EPS Estimate DriftChange to current

90d ago$-1.63+44.8%

60d ago$-1.77+49.2%

30d ago$-1.83+50.8%

7d ago$-0.900.0%

Current$-0.90

Revenue Consensus

Range$0 - $0

2 analysts

Period ending Dec 31, 2026

EPS Consensus$-1.49

Range$-1.49 - $-1.49

1 analysts

Revenue Consensus

Range$0 - $0

2 analysts

Period	Reported	Est.	Range	Surprise	B/M	Analysts	Revisions	YoY
Dec 31, 2026Dec 26EST	-	$-1.49	$-1.49 - $-1.49	-	-	1	-	-
Sep 30, 2026Sep 26EST	-	$-0.90	$-0.90 - $-0.90	-	-	1	No revisions (30d)	-
Jun 30, 2026Jun 26 Reported Aug 6, 2026Reported Aug 6	$-1.84	$-1.98	$-2.03 - $-1.84	+7.07%	Beat	4	No revisions (30d)	+83.7%
Mar 31, 2026Mar 26 Reported May 7, 2026Reported May 7	$-1.87	$-2.03	$-2.40 - $-1.81	+7.88%	Beat	3	2 0 30d	+60.0%
Dec 31, 2025Dec 25 Reported Mar 5, 2026Reported Mar 5	$-0.81	N/A	-	+64.63%	Beat	3	3 0 30d	-97.6%
Sep 30, 2025Sep 25 Reported Nov 5, 2025Reported Nov 5	$-3.22	$-4.06	$-4.47 - $-3.65	+20.69%	Beat	3	1 0 30d	+34.6%
Jun 30, 2025Jun 25 Reported Aug 7, 2025Reported Aug 7	$-11.29	$-4.62	$-4.68 - $-4.55	-144.37%	Miss	2	1 0 30d	-71.1%
Mar 31, 2025Mar 25 Reported May 1, 2025Reported May 1	$-4.68	$-4.80	$-4.82 - $-4.78	+2.50%	Beat	2	0 1 30d	+25.2%
Dec 31, 2024Dec 24 Reported Mar 6, 2025Reported Mar 6	$-0.41	$-0.36	$-0.36 - $-0.36	-13.89%	Miss	1	0 1 30d	+21.2%
Sep 30, 2024Sep 24 Reported Nov 7, 2024Reported Nov 7	$-4.92	$-3.84	$-3.87 - $-3.82	-28.13%	Miss	2	No revisions (30d)	+19.6%
Jun 30, 2024Jun 24 Reported Aug 1, 2024Reported Aug 1	$-6.60	$-4.95	$-4.98 - $-4.91	-33.33%	Miss	3	No revisions (30d)	+14.1%
Mar 31, 2024Mar 24 Reported May 2, 2024Reported May 2	$-6.26	$-5.52	$-5.57 - $-5.49	-13.41%	Miss	4	No revisions (30d)	+10.1%
Dec 31, 2023Dec 23 Reported Mar 21, 2024Reported Mar 21	$-0.52	$-0.54	$-0.59 - $-0.48	+3.70%	Beat	4	No revisions (30d)	+16.1%
Sep 30, 2023Sep 23 Reported Nov 2, 2023Reported Nov 2	$-6.12	$-7.84	$-7.86 - $-7.81	+21.94%	Beat	4	No revisions (30d)	+25.0%
Jun 30, 2023Jun 23 Reported Aug 3, 2023Reported Aug 3	$-7.68	$-7.20	$-7.21 - $-7.18	-6.67%	Miss	3	No revisions (30d)	+1.5%
Mar 31, 2023Mar 23 Reported May 4, 2023Reported May 4	$-6.96	$-7.44	$-7.50 - $-7.39	+6.45%	Beat	4	No revisions (30d)	+21.6%
Dec 31, 2022Dec 22 Reported Mar 2, 2023Reported Mar 2	$-0.62	$-0.66	$-0.76 - $-0.59	+6.06%	Beat	6	No revisions (30d)	-1.6%
Sep 30, 2022Sep 22 Reported Nov 3, 2022Reported Nov 3	$-8.16	$-7.80	$-7.90 - $-7.59	-4.62%	Miss	7	No revisions (30d)	-4.6%
Jun 30, 2022Jun 22 Reported Aug 4, 2022Reported Aug 4	$-7.80	$-9.02	$-9.08 - $-8.94	+13.53%	Beat	6	No revisions (30d)	+0.0%
Mar 31, 2022Mar 22 Reported May 5, 2022Reported May 5	$-8.88	$-8.02	$-8.04 - $-7.99	-10.72%	Miss	6	No revisions (30d)	-23.3%
Dec 31, 2021Dec 21 Reported Mar 3, 2022Reported Mar 3	$-0.61	$-0.67	$-0.74 - $-0.54	+8.96%	Beat	8	No revisions (30d)	-13.0%
Sep 30, 2021Sep 21 Reported Nov 4, 2021Reported Nov 4	$-7.80	$-7.97	$-8.00 - $-7.94	+2.13%	Beat	9	No revisions (30d)	-10.2%
Jun 30, 2021Jun 21 Reported Aug 5, 2021Reported Aug 5	$-7.80	$-7.44	$-7.48 - $-7.39	-4.84%	Miss	7	No revisions (30d)	-22.6%
Mar 31, 2021Mar 21 Reported May 6, 2021Reported May 6	$-7.20	$-7.15	$-7.24 - $-7.10	-0.70%	Miss	6	No revisions (30d)	-2281.8%
Dec 31, 2020Dec 20 Reported Mar 4, 2021Reported Mar 4	$-0.54	$-0.60	$-0.66 - $-0.50	+10.00%	Beat	9	No revisions (30d)	+86.8%
Sep 30, 2020Sep 20 Reported Nov 5, 2020Reported Nov 5	$-7.08	$-6.52	$-6.67 - $-6.39	-8.59%	Miss	8	No revisions (30d)	-59.5%
Jun 30, 2020Jun 20 Reported Aug 6, 2020Reported Aug 6	$-6.36	$-5.82	$-5.95 - $-5.67	-9.28%	Miss	9	1 0 30d	+13.1%
Mar 31, 2020Mar 20 Reported May 7, 2020Reported May 7	$0.33	$-0.44	$-1.31 - $0.23	+175.00%	Beat	7	1 0 30d	+107.4%
Dec 31, 2019Dec 19 Reported Mar 12, 2020Reported Mar 12	$-4.08	N/A	-	+51.77%	Beat	7	No revisions (30d)	-
Sep 30, 2019Sep 19 Reported Nov 12, 2019Reported Nov 12	$-4.44	$-4.08	$-4.09 - $-4.07	-8.82%	Miss	2	No revisions (30d)	-
Jun 30, 2019Jun 19 Reported Aug 12, 2019Reported Aug 12	$-7.32	$-7.56	$-7.73 - $-7.40	+3.17%	Beat	2	No revisions (30d)	-
Mar 31, 2019Mar 19 Reported Jun 10, 2019Reported Jun 10	$-4.46	$-0.53	-	-741.51%	Miss	-	-	-

Key Metrics

Valuation
P/E Ratio	-0.89	EV/EBITDA	N/A
Price/FCF	N/A	FCF Yield	N/A
Profitability
Profit Margin	0.00%	Operating Margin	0.00%
ROE	-204.60%	ROIC	-214.39%
Financial Health
Debt/Equity	0.30x	Interest Coverage	N/A
Current Ratio	3.47x	Quick Ratio	3.47x
Trading Statistics
Beta	1.35	Avg Volume	96.01K
52-Week High	$15.74	52-Week Low	$1.55

Technical Indicators Dashboard

Moving Averages

SMA 10$6.27

SMA 20$5.73

SMA 50$6.39

SMA 200$8.28

EMA 10$6.35

EMA 20$6.15

EMA 50$6.02

EMA 200$6.99

MACD

Line: 0.17Signal: -0.01Hist: 0.18

ADX

ADX: 26.0+DI: 24.4-DI: 10.9

Aroon & PSAR

Aroon UpN/A

Aroon Down36.0

PSAR$5.49

Bollinger Bands

Upper Band$7.33

Lower Band$4.12

%B Position5605%(Upper)

Band Width0.86

RSI (14-Day)

Neutral

58.5

Momentum Oscillators

Stoch %K65.7

Stoch %D67.8

Williams %R-23.4

ROC (10d)38.7%

Momentum1.92

CCI (20d)119.5

MFI (14d)64.2

Volatility Measures

ATR (14d)$0.77(11.2%)

StdDev (20d)0.80

Hist Vol111.8%(High)

Volume Flow

VWAP$6.89

OBV117.5M

AD Line2.6B

CMF (20d)-0.044

Volume Metrics

Avg Vol (20d)94.9K

Vol Ratio0.8x

VWMA (20d)$5.70

Pivot Points

R3$7.67

R2$7.26

R1$6.92

Pivot Point$6.52

S1$6.17

S2$5.77

S3$5.43

Advanced Oscillators

TSI6.42

Ultimate Osc60.3

KST-31.89

Financial Data

Quarter	Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024	Jun 2024	Mar 2024	Dec 2023	Sep 2023
Total Revenue	$0	$0	$0	$0	$0	$0	$3.28M	$0	$0	$0	$6.28M	$0
Cost of Revenue	$0	$0	$365,000	$0	$0	$0	N/A	$0	$0	$0	$824,000	$0
Gross Profit	$0	$0	$-365,000	$0	$0	$0	$1.64M	$0	$0	$0	$5.46M	$0

Operating Expenses	$15.09M	$10.11M	$9.76M	$8.95M	$27.29M	$11.62M	$12.46M	$12.49M	$16.49M	$18.30M	$15.79M	$15.62M
R&D	$7.42M	$6.83M	$6.80M	$6.14M	$24.09M	$7.90M	$8.90M	$8.77M	$12.42M	$11.40M	$11.83M	$11.01M
SG&A	$2.59M	$3.27M	$2.96M	$2.81M	$3.20M	$3.73M	$3.55M	$3.73M	$4.08M	$4.36M	$3.96M	$4.61M
Operating Income	$-15,094,000	$-10,105,000	$-9,757,000	$-8,945,000	$-27,292,000	$-11,622,000	$-12,455,000	$-12,495,000	$-16,494,000	$-18,304,000	$-15,790,000	$-15,618,000

Interest Income	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Interest Expense	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$3.59M	$0
Income Before Tax	$-14,892,000	$-9,796,000	$-9,436,000	$-8,624,000	$-26,808,000	$-10,976,000	$-11,603,000	$-11,540,000	$-15,404,000	$-17,107,000	$-19,381,000	$-14,301,000
Income Tax Expense	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0

Net Income	$-14,892,000	$-9,796,000	$-9,436,000	$-8,624,000	$-26,808,000	$-10,976,000	$-11,603,000	$-11,540,000	$-15,404,000	$-17,107,000	$-14,467,000	$-14,301,000

EBITDA	$-14,661,000	$-9,572,000	$-9,120,000	$-8,137,000	$-26,324,000	$-10,559,000	$-11,212,000	$-11,173,000	$-15,013,000	$-16,621,000	$-15,290,000	$-13,673,000
EBIT	$-14,892,000	$-9,796,000	$-9,436,000	$-8,624,000	$-26,808,000	$-10,976,000	$-11,603,000	$-11,540,000	$-15,404,000	$-17,107,000	$-15,790,000	$-14,301,000

* Some calculated fields are derived from available data when not provided by source

Related GNG Research

No research available

Be the first to write about NXTC

News

NextCure seeks court validation of 1-for-12 split: NextCure stock faces November 6 hearing

NextCure is seeking court validation for its 1-for-12 reverse stock split, a critical legal step for its proposed merger with Avere Therapeutics. The Delaware Court of Chancery will hold a hearing on November 6, 2026...

ad-hoc-news.de•Oct 15, 2026 10:11 PM ET10/15/26•Neutral

NextCure stock faces a November court test over its reverse split

NextCure (NXTC) faces a Delaware court hearing on November 6, 2026, regarding its 1-for-12 reverse stock split...

AD HOC NEWS•Oct 6, 2026 9:48 AM ET10/6/26•Somewhat-Bearish

NextCure stock fell 3.79 percent as court review loomed

NextCure stock dropped 3.79 percent to $5.08 on September 25, 2026, ahead of a November 6, 2026 Delaware court hearing regarding the validation of its 1-for-12 reverse stock split. The company reported a Q2 net loss...

AD HOC NEWS•Sep 29, 2026 1:16 AM ET9/29/26•Bearish

NextCure seeks Delaware court validation of 2025 1-for-12 reverse split ahead of Avere merger

NextCure has filed a Section 205 petition in the Delaware Court of Chancery to validate its July 2025 1-for-12 reverse stock split and related share issuance. The validation is sought to address uncertainty impacting...

TradingView•Sep 25, 2026 6:19 PM ET9/25/26•Neutral

About 90% of votes cast backed a share split. NextCure (NXTC) now asks a court to validate it.

NextCure Inc. has petitioned the Delaware Court of Chancery to validate its 2025 1-for-12 reverse stock split. The company is seeking validation due to recent amendments to Delaware law concerning voting standards...

Stock Titan•Sep 25, 2026 6:19 PM ET9/25/26•Neutral

NXTC Valuation and Fair Value

P/E: -0.9x
P/B: 3.0x

See GNG's fair value

NXTC Profitability: Margins, ROIC and FCF

Operating margin: 0.0%
Net margin: 0.0%
ROIC: -214.4%
ROE: -204.6%

NXTC Competitors

Company	Ticker
DocGo Inc	DCGO
Nortech Systems Incorporated	NSYS
Barinthus Biotherapeutics plc	BRNS
Picard Medical, Inc.	PMI
Actinium Pharmaceuticals Inc	ATNM
Sangamo Therapeutics Inc	SGMO
Milestone Scientific	MLSS
Evoke Pharma Inc	EVOK

Sector: Healthcare

NXTC Analyst Ratings

Consensus: Buy
Analysts: 3
Strong Buy: 1
Buy: 2
Hold: 0
Sell: 0
Strong Sell: 0

NXTC Bull Case vs Bear Case

Bear case

NXTC's quarterly revenue changed -100.0% year over year.

NXTC Earnings: Beat Rate and Next Report

Beat rate: 5 of 8 quarters (62.5%)
Average surprise: -10.5%
EPS estimate (fiscal period ending Sep 30, 2026): $-0.90
Estimate revisions (30 days, fiscal period ending Sep 30, 2026): 0 up, 0 down

Frequently Asked Questions About NXTC

Does NXTC pay dividends?

NextCure Inc (NXTC) does not currently pay a regular dividend.

What is NXTC's market cap?

NextCure Inc (NXTC) has a market capitalization of $30.12M with a current stock price of $6.88.

Get full access to GNG Research

Create a free account to access portfolio tracking, advanced tools, and more.

Create Free Account Log In